Unknown

Dataset Information

0

The Female Genital Tract Microbiome Is Associated With Vaginal Antiretroviral Drug Concentrations in Human Immunodeficiency Virus-Infected Women on Antiretroviral Therapy.


ABSTRACT: Background:The female genital tract (FGT) microbiome may affect vaginal pH and other factors that influence drug movement into the vagina. We examined the relationship between the microbiome and antiretroviral concentrations in the FGT. Methods:Over one menstrual cycle, 20 human immunodeficiency virus (HIV)-infected women virologically suppressed on tenofovir (TFV) disoproxil fumarate/emtricitabine and ritonavir-boosted atazanavir (ATV) underwent serial paired cervicovaginal and plasma sampling for antiretroviral concentrations using high-performance liquid chromatography-tandem mass spectrometry. Analysis of 16S ribosomal RNA gene sequencing of cervicovaginal lavage clustered each participant visit into a unique microbiome community type (mCT). Results:Participants were predominantly African American (95%), with a median age of 38 years. Cervicovaginal lavage sequencing (n = 109) resulted in a low-diversity mCT dominated by Lactobacillus (n = 40), and intermediate-diversity (n = 28) and high-diversity (n = 41) mCTs with abundance of anaerobic taxa. In multivariable models, geometric mean FGT:plasma ratios varied significantly by mCT for all 3 drugs. For both ATV and TFV, FGT:plasma was significantly lower in participant visits with high- and low-diversity mCT groups (all P < .02). For emtricitabine, FGT:plasma was significantly lower in participant visits with low- vs intermediate-diversity mCT groups (P = .002). Conclusions:Certain FGT mCTs are associated with decreased FGT antiretroviral concentrations. These findings are relevant for optimizing antiretrovirals used for biomedical HIV prevention in women.

SUBMITTER: Donahue Carlson R 

PROVIDER: S-EPMC5853913 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

The Female Genital Tract Microbiome Is Associated With Vaginal Antiretroviral Drug Concentrations in Human Immunodeficiency Virus-Infected Women on Antiretroviral Therapy.

Donahue Carlson Renee R   Sheth Anandi N AN   Read Timothy D TD   Frisch Michael B MB   Mehta C Christina CC   Martin Amy A   Haaland Richard E RE   Patel Anar S AS   Pau Chou-Pong CP   Kraft Colleen S CS   Ofotokun Igho I  

The Journal of infectious diseases 20171101 8


<h4>Background</h4>The female genital tract (FGT) microbiome may affect vaginal pH and other factors that influence drug movement into the vagina. We examined the relationship between the microbiome and antiretroviral concentrations in the FGT.<h4>Methods</h4>Over one menstrual cycle, 20 human immunodeficiency virus (HIV)-infected women virologically suppressed on tenofovir (TFV) disoproxil fumarate/emtricitabine and ritonavir-boosted atazanavir (ATV) underwent serial paired cervicovaginal and p  ...[more]

Similar Datasets

| S-EPMC6667798 | biostudies-literature
| S-EPMC6798248 | biostudies-literature
| S-EPMC4013016 | biostudies-literature
| S-EPMC2950605 | biostudies-literature
| S-EPMC8260895 | biostudies-literature
| S-EPMC7146007 | biostudies-literature
| S-EPMC4324201 | biostudies-literature
| S-EPMC8648917 | biostudies-literature
| S-EPMC8790106 | biostudies-literature
2025-03-28 | PXD046053 | Pride